Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt small index

Solid Tumor Cancer: early-phase trial registry

9 of 11 indexed Solid Tumor Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 9 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Solid Tumor Cancer: 11 US clinical trials tracked, 9 recruiting.

Solid Tumor Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Avenzo Therapeutics, running 2 of these trials.

Enrollment posture brief

Registry condition solid-tumor-cancer

OPEN 9 | RECR 82% | LATE 0 | EARLY 6 | RANK #1577 | SPON 2

Nearest open-share peer: Gynecologic Cancers (82% recruiting · 11 trials)

Solid Tumor Cancer (this)82%Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Solid Tumor Cancer

Solid Tumor Cancer lists 9 open slots (82% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Solid Tumor Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Solid Tumor Cancer is recruiting above its size-band peers.

    9 of 11 indexed trials (81.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Solid Tumor Cancer research.

    Avenzo Therapeutics accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Solid Tumor Cancer enrolment sits around 100 participants.

    Median target enrolment is 100 among the 11 trials that report a genuine target (sentinel values excluded). 5 of those (45.5%) plan for fewer than 100 participants.

  4. Solid Tumor Cancer research is mostly interventional.

    9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16

Open and recent trials

11 total, page 1 of 1

RECRUITING 7,000 participants

A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

OWKIN

NCT06625203

RECRUITING Phase 1 430 participants

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Avenzo Therapeutics

NCT07038343

RECRUITING Phase 1 386 participants

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Conjupro Biotherapeutics

NCT07424547

RECRUITING Phase 1 355 participants

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Avenzo Therapeutics

NCT07193511

RECRUITING NA 100 participants

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

Fred Hutchinson Cancer Center

NCT06802172

RECRUITING 100 participants

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Washington University School of Medicine

NCT04354064

RECRUITING NA 50 participants

A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer

Memorial Sloan Kettering Cancer Center

NCT07117461

RECRUITING NA 50 participants

Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application

University of Pittsburgh

NCT07218874

RECRUITING Phase 1 36 participants

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

Pilatus Biosciences

NCT07337525

COMPLETED Phase 1 30 participants

SB-743921 In Patients With Solid Tumors

GlaxoSmithKline

NCT00136513

COMPLETED Phase 1 25 participants

Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

GlaxoSmithKline

NCT00085878

Phase Distribution

PhaseTrial count
Phase 1 6

Named interventions

Most-linked intervention names on Solid Tumor Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

SB-743921 Drug
1 trials
SB-485232 Drug
1 trials
Mobile Symptom Monitoring and Alert App Behavioral
1 trials
Combination Agent 2 Drug
1 trials
Combination Agent 1 Drug
1 trials
AVZO-1418 Drug
1 trials
Combination Agent Drug
1 trials
AVZO-103 Drug
1 trials

US sites by state

Facility locations filed on Solid Tumor Cancer trials. A trial with sites in several states counts in each.

Pennsylvania 5 trials
Texas 4 trials
Florida 3 trials
Virginia 2 trials
Massachusetts 2 trials
California 2 trials
Wisconsin 1 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Solid Tumor Cancer page

11 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor Cancer condition card totals 11 registered trials; most-linked intervention SB-743921; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.